Overview

Study to Determine the Onset of Action of Indacaterol in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Status:
Completed

Trial end date:
2008-08-01

Target enrollment:

Participant gender:

Summary

This study will evaluate the onset of action of indacaterol (150 and 300 µg) as compared to placebo, salbutamol 200 µg and salmeterol/fluticasone 50/500 µg

Phase:

Phase 3

Details

Lead Sponsor:

Novartis

Treatments:

Albuterol
Fluticasone
Salmeterol Xinafoate
Xhance